An investigational treatment that is administered antenatally to treat the rare genetic disorder X-linked hypohidrotic ectodermal dysplasia (XLHED) in babies has become the first product for a dermatological condition to make it onto the European Medicines Agency’s PRIME (priority medicines) scheme.
ER004, a biological that is being developed by Swiss non-for-profit organization EspeRare Foundation, was one of three products to be accepted onto PRIME this month by the EMA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?